CureVac (NASDAQ:CVAC) Receives "Market Outperform" Rating from JMP Securities

CureVac (NASDAQ:CVAC - Get Free Report)'s stock had its "market outperform" rating reiterated by research analysts at JMP Securities in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $10.00 price target on the stock. JMP Securities' target price would indicate a potential upside of 120.75% from the company's current price.

Separately, UBS Group reduced their price target on shares of CureVac from $13.00 to $12.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th.

CureVac Stock Down 2.2%

Shares of NASDAQ:CVAC traded down $0.10 during trading on Wednesday, hitting $4.53. 853,039 shares of the company were exchanged, compared to its average volume of 740,591. The stock has a market capitalization of $1.02 billion, a P/E ratio of 8.24 and a beta of 2.43. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. CureVac has a 12-month low of $2.37 and a 12-month high of $5.28. The firm's 50 day moving average price is $3.35 and its 200-day moving average price is $3.33.

CureVac (NASDAQ:CVAC - Get Free Report) last released its quarterly earnings results on Thursday, May 22nd. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.08). CureVac had a net margin of 20.72% and a return on equity of 21.98%. The business had revenue of $0.94 million during the quarter, compared to analysts' expectations of $4.27 million. On average, research analysts predict that CureVac will post 0.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CureVac

Several institutional investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC increased its stake in CureVac by 25.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company's stock valued at $42,000 after buying an additional 3,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in CureVac by 14.3% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,125 shares of the company's stock valued at $81,000 after buying an additional 3,648 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in CureVac by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company's stock valued at $162,000 after buying an additional 4,425 shares during the period. Signaturefd LLC increased its stake in CureVac by 29.2% in the 4th quarter. Signaturefd LLC now owns 36,140 shares of the company's stock valued at $123,000 after buying an additional 8,170 shares during the period. Finally, Greenleaf Trust acquired a new position in CureVac in the 1st quarter valued at $31,000. 17.26% of the stock is owned by institutional investors and hedge funds.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.